Syndax Pharmaceuticals (SNDX) EBT (2015 - 2026)

Syndax Pharmaceuticals' EBT history runs 12 years deep, the most recent figure standing at -$42.4 million for Q1 2026.

• On a quarterly basis, EBT rose 49.82% year-over-year to -$42.4 million in Q1 2026; TTM through Mar 2026 was -$236.9 million, a 29.91% increase from a year earlier, with the FY2025 full-year figure at -$307.2 million, up 46.31% from the prior year.
• EBT climbed to -$42.4 million in Q1 2026 per SNDX's latest filing, from -$58.2 million in the prior quarter.
• Across five years, EBT topped out at -$34.6 million in Q4 2022 and bottomed at -$94.1 million in Q4 2024.
• The 5-year median for EBT is -$57.2 million (2023), against an average of -$59.3 million.
• Across the five-year window, EBT tumbled 136.24% in 2022 and soared 49.82% in 2026, its largest moves.
• Year by year, EBT stood at -$34.6 million in 2022, then plunged by 65.42% to -$57.2 million in 2023, then plunged by 64.7% to -$94.1 million in 2024, then soared by 38.15% to -$58.2 million in 2025, then advanced by 27.1% to -$42.4 million in 2026.
• Per Business Quant, the three latest SNDX EBT figures stand at -$42.4 million (Q1 2026), -$58.2 million (Q4 2025), and -$60.5 million (Q3 2025).